98%
921
2 minutes
20
Purpose: To prospectively evaluate the value of Vesical Imaging Reporting and Data System (VI‑RADS) prior to initial transurethral resection of the bladder (TURB) in predicting residual tumor at second TURB and subsequent prognosis of patients.
Methods: We enrolled suspected bladder cancer patients and scheduled multiparametric magnetic resonance imaging (mpMRI) of bladder for them before initial TURB. Second TURB were conducted based on initial resection reports, with comparisons made between patients with VI-RADS scores <3 and ≥3 regarding residual tumor rate, recurrence-free survival (RFS) and progression-free survival (PFS). Predictive efficacy of VI-RADS was assessed using Chi-square tests, logistic and Cox regression analyses, ROC curves, and Kaplan-Meier analyses.
Results: A total of 108 patients were included, and residual tumors were detected in 25.0% (27/108) of them at second TURB, with a significant difference between patients with VI-RADS score <3 and ≥3 (8/81 vs. 19/27, p <0.001). VI-RADS ≥3 demonstrated a sensitivity of 70.4%, specificity of 90.1%, positive predictive value (PPV) of 70.4%, and negative predictive value (NPV) of 90.1%. Stratified analysis showed VI-RADS achieved a NPV of 95.2% for disease-free Ta patients, while 84.6% for T1 patients. After a median follow-up of 30 months for the 92 patients, 24 experienced tumor recurrence. VI-RADS ≥3 was found to be an independent predictor of tumor recurrence (HR = 4.297, p = 0.003).
Conclusions: VI-RADS ≥3 is associated with higher residual tumor rate at second TURB and higher recurrence risk. It might be an option for omitting second TURB when VI-RADS is <3, especially for Ta patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00345-025-05666-6 | DOI Listing |
Driven by eutrophication and global warming, the occurrence and frequency of harmful cyanobacteria blooms (CyanoHABs) are increasing worldwide, posing a serious threat to human health and biodiversity. Early warning enables precautional control measures of CyanoHABs within water bodies and in water works, and it becomes operational with high frequency in situ data (HFISD) of water quality and forecasting models by machine learning (ML). However, the acceptance of early warning systems by end-users relies significantly on the interpretability and generalizability of underlying models, and their operability.
View Article and Find Full Text PDFInt Urol Nephrol
August 2025
Department of Urology, University of Health Sciences, Ankara City Hospital, Üniversiteler Mahallesi 1604. Cadde No: 9 Çankaya, 06800, Ankara, Turkey.
Purpose: To evaluate different protocols to increase the efficacy and reliability of single, immediate intravesical postoperative chemotherapy (IPOC) after transurethral bladder tumour resection (TURBT).
Methods: A retrospective evaluation was made of 104 patients, who underwent TURBT between October 2020 and October 2022, and were subsequently administered IPOC. The patients were examined in two groups as infusion IPOC (n:50) and bolus IPOC (n:54).
Aktuelle Urol
June 2025
Urology, Urologische Klinik Planegg, Planegg, Germany.
The diagnosis and staging of bladder cancer is challenging. TUR-B and CT diagnostics bear limitations in detecting muscle invasion and perivesical fat invasion. Thus, second TUR-B is required to ensure more reliable pathological staging.
View Article and Find Full Text PDFWorld J Urol
May 2025
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China.
Purpose: To prospectively evaluate the value of Vesical Imaging Reporting and Data System (VI‑RADS) prior to initial transurethral resection of the bladder (TURB) in predicting residual tumor at second TURB and subsequent prognosis of patients.
Methods: We enrolled suspected bladder cancer patients and scheduled multiparametric magnetic resonance imaging (mpMRI) of bladder for them before initial TURB. Second TURB were conducted based on initial resection reports, with comparisons made between patients with VI-RADS scores <3 and ≥3 regarding residual tumor rate, recurrence-free survival (RFS) and progression-free survival (PFS).
Clin Genitourin Cancer
June 2025
Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Introduction And Objectives: Non-muscle-invasive bladder cancer (NMIBC) patients need a strict follow-up with cystoscopy (UCS) and voided urinary cytology (vUC) due to high rate of recurrence and progression. To reduce invasiveness and costs, a new diagnostic biomarker, namely Xpert Monitor BC-detecting 5 mRNAs in voided urine-, has been proposed. We test Xpert Monitor BC ability to detect tumor recurrence at an early point during follow-up of high risk (HR) or very high risk (VHR) NMIBC patients, aiming at evaluating reliability of this test as a single procedure.
View Article and Find Full Text PDF